NASH is associated with a significant risk of cirrhosis, hepatocellular carcinoma, and liver failure, underscoring the urgency of developing effective therapeutic strategies targeting key molecular pathways such as those regulated by MST1. The gene discussed is MST1; the disease is metabolic dysfunction-associated steatohepatitis.